Patents by Inventor Stephen T. Warren

Stephen T. Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS
    Publication number: 20150359766
    Abstract: mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety.
    Type: Application
    Filed: January 26, 2015
    Publication date: December 17, 2015
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • COMPOSITIONS FOR TREATING FRAGILE X AND OTHER DISORDERS METHODS OF USE THEREOF, AND SCREENING FOR COMPOUNDS FOR FRAGILE X AND OTHER DISORDERS
    Publication number: 20150174112
    Abstract: Methods of screening compounds, active compositions, pharmaceutical compositions, methods of treating disorders, methods of preventing disorders, and kits to screen a library of compounds, are disclosed.
    Type: Application
    Filed: March 9, 2015
    Publication date: June 25, 2015
    Inventors: Stephen T. Warren, Shuang Chang, Peng Jin
  • METHODS AND SYSTEMS FOR SCREENING FOR AND DIAGNOSING DNA METHYLATION ASSOCIATED WITH AUTISM SPECTRUM DISORDERS
    Publication number: 20120028816
    Abstract: Methods and systems for population screening and diagnostics are provided. In particular methods and systems for population screening of individuals for genetic disorders due to alterations in DNA methylation and for the diagnostic testing for such disorders are provided.
    Type: Application
    Filed: March 31, 2010
    Publication date: February 2, 2012
    Inventors: Stephen T. Warren, Reid S. Alisch
  • Methods of Treating Disorders with Group I mGluR Antagonists
    Publication number: 20100210542
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Application
    Filed: January 15, 2010
    Publication date: August 19, 2010
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating disorders with Group I mGluR antagonists
    Patent number: 7648993
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 19, 2010
    Assignees: Brown University, Emory University
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Compositions for Treating Fragile X and Other Disorders Methods of Use Thereof, and Screening for Compounds for Fragile X and Other Disorders
    Publication number: 20080312279
    Abstract: Methods of screening compounds, active compositions, pharmaceutical compositions, methods of treating disorders, methods of preventing disorders, and kits to screen a library of compounds, are disclosed.
    Type: Application
    Filed: October 26, 2006
    Publication date: December 18, 2008
    Inventors: Stephen T. Warren, Shuang Chang, Peng Jin
  • Method and identification of downstream mRNA ligands to FMRP and their role in fragile X syndrome and associated disorders
    Patent number: 7432052
    Abstract: Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal antibody to FMRP and a consensus sequence for the RNA binding region has been identified. Arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are provided. Additionally, methods for modulating RNA targets are provided.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: October 7, 2008
    Assignees: The Rockfeller University, Duke University, Emory University
    Inventors: Stephen T. Warren, Victoria Brown-Kennerly, Peng Jin, Stephanie Ceman, Robert B. Darnell, Jennifer C. Darnell, Jack D. Keene, Scott A. Tenenbaum
  • Methods of treating disorders with Group I mGluR antagonists
    Patent number: 6916821
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: July 12, 2005
    Assignees: Brown University, Emory University
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating disorders with group I mGluR antagonists
    Patent number: 6890931
    Abstract: Compositions and uses of mGluR5 antagonists for the treatment and prevention of neurological disorders, such as Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, are disclosed.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: May 10, 2005
    Assignees: Brown University, Emory University
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating disorders with Group I mGluR antagonists
    Publication number: 20040067978
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Application
    Filed: April 4, 2003
    Publication date: April 8, 2004
    Applicants: Brown University Research Foundation (BURF), Emory University
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating neurological disorders with group I mGluR antagonists
    Publication number: 20030100539
    Abstract: Compositions and uses of mGluR5 antagonists for the treatment and prevention of neurological disorders, such as Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, are disclosed.
    Type: Application
    Filed: April 2, 2002
    Publication date: May 29, 2003
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Diagnosis of the fragile X syndrome
    Patent number: 6180337
    Abstract: A sequence of the FMR-1 gene is disclosed. This sequence and related probes, cosmids and unique repeats are used to detect X-linked diseases and especially the fragile X syndrome. Also, methods using methylation-sensitive restriction endonuclease and PCR primer probes were used to detect X-linked disease.
    Type: Grant
    Filed: August 29, 1991
    Date of Patent: January 30, 2001
    Assignee: Baylor College of Medicine
    Inventors: C. Thomas Caskey, David L. Nelson, Maura Pieretti, Stephen T. Warren, Ben A. Oostra, Ying-hui Fu
  • Diagnosis of the fragile X syndrome
    Patent number: 6107025
    Abstract: A sequence of the FMR-1 gene is disclosed. This sequence and related probes, cosmids and unique repeats are used to detect X-linked diseases and especially the fragile X syndrome.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: August 22, 2000
    Assignee: Baylor College of Medicine
    Inventors: C. Thomas Caskey, David L. Nelson, Maura Pieretti, Stephen T. Warren, Ben A. Oostra